Hereditary Paraganglioma

Introduction

Hereditary Paraganglioma is an important component in the neurobiology of neurodegenerative . This page provides detailed information about its structure, function, and role in disease processes.

Hereditary paraganglioma syndromes are autosomal dominant disorders characterized by the development of tumors in the paraganglia, which are collections of neuroendocrine cells distributed throughout the head, neck, thorax, and abdomen. These tumors arise from the sympathetic and parasympathetic nervous systems and can produce catecholamines. The hereditary forms account for approximately 40% of all paragangliomas and are associated with germline mutations in genes encoding mitochondrial succinate dehydrogenase (SDH) complex subunits, highlighting the fundamental role of mitochondrial dysfunction in tumor pathogenesis. ^{1Incidental Discovery of Synchronous Ileal Neuroendocrine Tumors at Fluorodopa PET/CT in a Patient With Bilateral Pheochromocytoma}

Overview

Hereditary paraganglioma syndrome (HPS) represents a paradigm of mitochondrial tumor predisposition, where germline mutations in oxidative phosphorylation genes lead to tumor development through pseudohypoxic drive and dysregulated cellular metabolism. The syndrome demonstrates remarkable genotype-phenotype correlations, with specific gene mutations determining tumor location, catecholamine secretion patterns, and malignant potential. ^{2Mitochondrial contributions to tumor pathogenesis and therapeutic targeting2023 · PMID 37012452Open reference}

The condition follows an autosomal dominant inheritance pattern with maternal imprinting for SDHD, meaning that disease expression typically requires paternal transmission of the mutant allele. This unique inheritance pattern results in affected individuals often having an affected father, while the mother may carry the mutation without developing tumors. ^{3Phaeochromocytoma2005 · PMID 16109904Open reference}

Genetics and Molecular Pathogenesis

SDHx Gene Family

The SDHx genes encode subunits of succinate dehydrogenase (SDH), also known as mitochondrial Complex II, which plays a critical role in both the electron transport chain and the Krebs cycle: ^{4Inherited mutations in pheochromocytoma and paraganglioma: importance of sequential biochemical and genetic testing2013 · PMID 23471971Open reference}

| Gene | Protein | Chromosome | Tumor Risk | Malignancy Rate | [^6] |------|---------|------------|------------|-----------------| [^7] | SDHD | Subunit D | 11q23 | High | 5-10% | [^8] | SDHB | Subunit B | 1p36 | Very high | 30-50% | [^9] | SDHC | Subunit C | 1q23 | Moderate | <5% | [^10] | SDHAF2 | Assembly factor | 11q13 | High | <5% |

SDHAF2 and Additional Genes

Beyond the core SDHx subunits, mutations in SDHAF2 (also called SDH5) impair SDH assembly and function. Additional susceptibility genes include:

• TMEM127: Transmembrane protein involved in mTOR signaling

• MAX: MYC-associated factor, part of the MYC-MAX transcriptional network

• VHL: Von Hippel-Lindau disease, shares pseudohypoxia pathway

• RET: Multiple Endocrine Neoplasia type 2

Molecular Mechanisms of Tumorigenesis

The loss of functional SDH leads to several interconnected pathogenic :

1. Succinate accumulation: Blocked SDH activity causes succinate buildup

2. Prolyl hydroxylase inhibition: Succinate inhibits PHD enzymes

3. HIF-1α stabilization: Hypoxia-inducible factor accumulates

4. Pseudohypoxic drive: Tumors grow as if in low-oxygen conditions

5. Epigenetic dysregulation: Increased histone methylation from 2-oxoglutarate analogs

6. ROS production: Mitochondrial dysfunction increases reactive oxygen species

Clinical Presentation

Tumor Locations

Hereditary paragangliomas develop in characteristic locations depending on the underlying genetic mutation:

Head and Neck (Parasympathetic)

• Carotid body tumors (most common)

• Jugulotympanic paragangliomas

• Vagal paragangliomas

• Laryngeal paragangliomas

Thorax (Sympathetic)

• Mediastinal paragangliomas

• Aorticopulmonary tumors

Abdomen (Sympathetic)

• Abdominal paragangliomas

• Pheochromocytomas

• Extra-adrenal sympathetic tumors

Symptoms and Signs

Clinical manifestations depend on tumor location and catecholamine secretion:

• Neck mass: Painless, pulsatile neck mass

• Hoarseness: Vagal nerve involvement

• Dysphagia: Esophageal compression

• Catecholamine excess: Hypertension, headaches, palpitations, sweating

• Metastatic disease: Bone pain, weight loss (malignant cases)

Catecholamine Secretion Patterns

• SDHD/SDHC tumors: Usually non-functional

• SDHB tumors: Higher likelihood of catecholamine secretion

• Parasympathetic tumors: Typically non-secretory

• Sympathetic tumors: May produce norepinephrine predominantly

Diagnosis

Biochemical Testing

Initial evaluation includes biochemical assessment of catecholamine metabolism:

• Plasma free metanephrines: Most sensitive screening test

• 24-hour urine collection: Fractionated catecholamines and metanephrines

• Chromogranin A: Non-specific but elevated in most cases

• 3-methoxytyramine: Elevated in dopamine-secreting tumors

Imaging Studies

Localize tumors and assess for metastatic disease:

• MRI: Superior soft tissue resolution, T2 hyperintensity

• CT: Excellent for bone involvement

• 123I-MIBG scintigraphy: Functional imaging

• 68Ga-DOTATATE PET: Highest sensitivity for SDHB-related tumors

• 18F-FDG PET: Sensitive for metastatic disease

Genetic Testing

Given the high hereditary rate, genetic counseling and testing are essential:

• Comprehensive SDHx gene panel

• Extended panel including TMEM127, MAX, VHL, RET

• Pre-test and post-test genetic counseling

• Family cascade testing when pathogenic variant identified

Management

Surgical Treatment

Surgery remains the primary treatment modality:

• Preoperative preparation: Alpha-blockade for functional tumors

• Carotid body tumors: Careful dissection preserving carotid arteries

• Skull base tumors: Neurosurgical approach for intracranial extension

• Metastatic disease: Debulking for symptom relief

Radiation Therapy

For unresectable or residual disease:

• Stereotactic radiosurgery: Precise targeting

• External beam radiation: For larger tumors

• Yttrium-90 microspheres: Embolization with radioactive particles

Medical Therapy

For malignant or metastatic disease:

• Alpha-blockers: Phenoxybenzamine, doxazosin

• Beta-blockers: After adequate alpha-blockade

• Metyrosine: Inhibits tyrosine hydroxylase

• Chemotherapy: Cyclophosphamide, vincristine, dacarbazine

• Peptide receptor radionuclide therapy: 177Lu-DOTATATE

Surveillance

Long-term monitoring is critical:

• Annual biochemical testing

• Imaging every 1-2 years for non-metastatic disease

• More frequent imaging for SDHB mutation carriers

• Screening for related conditions (e.g., renal cell carcinoma with VHL)

Mitochondrial Dysfunction and Neurodegeneration

Shared Pathogenic Mechanisms

The mitochondrial dysfunction in hereditary paraganglioma shares with neurodegenerative :

1. Complex II impairment: SDH/Complex II dysfunction in both conditions

2. Pseudohypoxia response: HIF stabilization in neurodegeneration

3. Oxidative stress: ROS accumulation in neurons and tumor cells

4. Metabolic reprogramming: Warburg effect in tumors, metabolic changes in neurodegeneration

Parkinson’s Disease Connection

Epidemiological studies suggest potential links between SDHx variants and Parkinson’s disease risk:

• SDHx variants may modify PD susceptibility

• Shared mitochondrial Complex I and II dysfunction

• Potential therapeutic implications for both conditions

Therapeutic Implications

Understanding these connections suggests potential therapeutic strategies:

• Mitochondrial-targeted antioxidants: CoQ10, MitoQ, idebenone

• SDH activators: Novel compounds in development

• HIF inhibitors: For pseudohypoxic drive

• Autophagy enhancers: Rapamycin, trehalose

Prognosis

• Benign tumors: Excellent prognosis after complete resection

• SDHB mutations: 5-year survival 60-70% with metastatic disease

• SDHD/SDHC mutations: Generally excellent prognosis

• Recurrence risk: Higher with SDHB mutations

• Family screening: Essential for early detection

• Pheochromocytoma

• Mitochondrial Complex II

• Mitochondrial Dysfunction

• Oxidative Stress

• Von Hippel-Lindau Disease

• Multiple Endocrine Neoplasia

• Parkinson’s Disease

External Links

• National Cancer Institute - Paraganglioma

• SDH-Deficient GIST Consortium

• Hereditary Paraganglioma-Pheochromocytoma Research Foundation

Background

The study of Hereditary Paraganglioma has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Recent Research (2024-2026)

This section highlights recent publications relevant to this disease.

• An Isolated Soft Tissue Ectopic Paraganglioma in the Head and Neck. (2026 Apr) - Head & neck

• Incidental Discovery of Synchronous Ileal Neuroendocrine Tumors at Fluorodopa PET/CT in a Patient With Bilateral Pheochromocytoma. (2026 Apr 1) - Clinical nuclear medicine

• Pseudohypoxia and Family History Are Key Predictors of Severe Outcomes in Hereditary Pheochromocytoma and Paraganglioma Syndromes. (2026 Mar 5) - European journal of endocrinology

• Succinate dehydrogenase-deficient cancer cells have increased susceptibility to Ym155-induced DNA damage. (2026 Mar 1) - Endocrine-related cancer

• Who can safely discontinue lifelong follow-up among patients with sporadic pheochromocytoma and paraganglioma? (2026 Mar 4) - Journal of internal medicine